Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
- Promethera Kicks Off PIIb Study of Cell-Based Therapy HepaStem for ACLF in Europe
January 9, 2020
- Chugai Chairman Pushes for Industry Shakeup, Govt Initiative to Develop Ecosystem
January 8, 2020
- Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
January 8, 2020
- Meiji Seika Forms JV with US Startup to Develop, Commercialize cGVHD Treatment
January 8, 2020
- Kyorin Grabs Japan Rights to aTyr’s Immunomodulator
January 7, 2020
- Taiho, Astex in KRAS Licensing Deal with US Merck
January 7, 2020
- Kyowa Kirin’s Parkinson’s Med Accepted for Review in Europe
January 7, 2020
- Eisai’s Fycompa Now Available in China
January 7, 2020
- Ono, Seikagaku File Novel Osteoarthritis Treatment in Japan
January 7, 2020
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
- Urovant, Now under Sumitomo Dainippon, Seeks US Approval for Vibegron
January 7, 2020
- Eisai Discontinues Development of Epilepsy Drug after Death in PI; “Will Never Be Administered to Humans in the Future”
January 6, 2020
- Astellas Snaps Up US Biotech Xyphos for I/O Technology Platform
January 6, 2020
- Maruho Becomes Solasia’s 2nd Largest Shareholder
January 6, 2020
- Chugai’s Companion Diagnostic OK’ed for Rozlytrek’s ROS1 Use
December 27, 2019
- I/O Biotech BrightPath, Osaka Univ. Link Up for R&D of Immunostimulants
December 27, 2019
- Xofluza Most Detailed Drug for GPs in November: Impact Track
December 26, 2019
- IBL Inks Tick-Borne Disease Deal with South Korea Firm
December 26, 2019
- Nippon BI Chair Thorsten Poehl to Double as President after Merger; Yoshiaki Aono to Head Pharma Biz
December 26, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…